One week after launching a dedicated CRISPR program, Qiagen partnered with San Diego-based Verogen to provide next-generation sequencing human identification workflows to laboratories in order to support forensic efforts from justice departments across the globe.
The World Health Organization asked six African countries to be alert for possible Ebola infections, as Guinea on Feb. 16 reported new cases and Democratic Republic of Congo said its new infections were a resurgence of a previous outbreak.
Bay Area-based Graphite Bio launched with $45 million in Series A financing and a goal to use gene editing to correct defective genes through high-efficiency site-specific integration of new genetic sequences.
The Federal Trade Commission filed a complaint aimed at stopping Illumina Inc. from purchasing Pacific Biosciences of California.
Unfortunately, 2018 marked yet another bad year for Alzheimer’s disease drug development, with at least half-a-dozen major clinical drug trial failures.
Gene sequencing company Illumina Inc. plans to buy Pacific Biosciences of California Inc. in an all-cash deal valued at $1.2 billion.
Brooks Automation will increase the automation and cryogenics specialist’s toehold in the life sciences industry with a $450 million all-cash acquisition of genomic services group Genewiz.
Swiss drugmaker Roche upped the company’s bet on personalized cancer treatment and is ready to sell a blood test around the world that can identify common gene mutations from solid tumors from a patient’s blood.
Genomic company 23andMe halted its plans to develop a new gene-sequencing program that would have allowed customers to learn more about potential predisposition to genetic diseases.
Gene sequencing of more than 1,000 children and adolescents diagnosed with cancer found that as many as 8.5 percent were born with genes that increase their risk of developing cancer, U.S. researchers said on Wednesday. Of the children with cancer risk genes, only 40 percent came from families with a known history of cancer, suggesting […]